Forte Biosciences (FBRX) Change in Accured Expenses (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Change in Accured Expenses of $439000.0 for Q1 2026, down 74.01% year-over-year from $1.7 million in Q1 2025, and down 86.54% quarter-over-quarter from $3.3 million in Q4 2025.
Powered by 
Analysis
Forte Biosciences (FBRX) Change in Accured Expenses (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Change in Accured Expenses for 11 consecutive years, with $439000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 74.01% year-over-year to $439000.0; the TTM figure through Mar 2026 stood at $7.2 million (up 198.87% YoY), while the FY2025 annual figure was $8.4 million, up 7608.26% from the prior year.
- Change in Accured Expenses eased to $439000.0 in Q1 2026 per FBRX's latest filing, from $3.3 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $3.6 million in Q3 2025 and bottomed at -$1.2 million in Q3 2023.
- Historically, Change in Accured Expenses has averaged $608823.5 across 5 years, with a median of $287000.0 in 2022.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses tumbled 955.2% — and 2025, when it jumped 960.66%.
- Forte Biosciences' Change in Accured Expenses stood at $924000.0 in 2022, then tumbled by 86.47% to $125000.0 in 2023, then sank by 955.2% to -$1.1 million in 2024, then surged by 405.14% to $3.3 million in 2025, then slumped by 86.54% to $439000.0 in 2026.
- Business Quant data shows FBRX's Change in Accured Expenses at $439000.0 in Q1 2026, $3.3 million in Q4 2025, and $3.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | -4.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.92 Mn |
| Mar 31, 2026 | 439,000.00 |
| Dec 31, 2025 | 3.26 Mn |
| Sep 30, 2025 | 3.63 Mn |
| Jun 30, 2025 | -181,000.00 |
| Mar 31, 2025 | 1.69 Mn |
| Dec 31, 2024 | -1.07 Mn |
| Sep 30, 2024 | -422,000.00 |
| Jun 30, 2024 | 2.20 Mn |
| Mar 31, 2024 | -595,000.00 |
| Dec 31, 2023 | 125,000.00 |
| Sep 30, 2023 | -1.18 Mn |
| Jun 30, 2023 | 846,000.00 |
| Mar 31, 2023 | 392,000.00 |
| Dec 31, 2022 | 924,000.00 |
| Sep 30, 2022 | 287,000.00 |
| Jun 30, 2022 | 135,000.00 |
| Mar 31, 2022 | -132,000.00 |
| Dec 31, 2021 | -598,000.00 |
| Sep 30, 2021 | -583,000.00 |